000862731 001__ 862731
000862731 005__ 20240625095110.0
000862731 0247_ $$2doi$$a10.18632/oncotarget.26848
000862731 0247_ $$2Handle$$a2128/22309
000862731 0247_ $$2altmetric$$aaltmetric:59154050
000862731 0247_ $$2pmid$$apmid:31105869
000862731 037__ $$aFZJ-2019-02974
000862731 082__ $$a610
000862731 1001_ $$0P:(DE-HGF)0$$aKotredes, Kevin P.$$b0
000862731 245__ $$aCharacterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
000862731 260__ $$a[S.l.]$$bImpact Journals LLC$$c2019
000862731 3367_ $$2DRIVER$$aarticle
000862731 3367_ $$2DataCite$$aOutput Types/Journal article
000862731 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1560429555_27296
000862731 3367_ $$2BibTeX$$aARTICLE
000862731 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000862731 3367_ $$00$$2EndNote$$aJournal Article
000862731 520__ $$aThe family of isocitrate dehydrogenase (IDH) enzymes is vital for cellular metabolism, as IDH1 and IDH2 are required for the decarboxylation of isocitrate to α-ketoglutarate. Heterozygous somatic mutations in IDH1 or IDH2 genes have been detected in many cancers. They share the neomorphic production of the oncometabolite (R)-2-hydroxyglutarate [(R)-2-HG]. With respect to IDH2, it is unclear whether all IDH2 mutations display the same or differ in tumorigenic properties and degrees of chemosensitivity. Here, we evaluated the three most frequent IDH2 mutations occurring in cancer. The predicted changes to the enzyme structure introduced by these individual mutations are supported by the observed production of (R)-2-HG. However, their tumorigenic properties, response to chemotherapeutic agents, and baseline activation of STAT3 differed. Paradoxically, the varying levels of endogenous (R)-2-HG produced by each IDH2 mutant inversely correlated with their respective growth rates. Interestingly, while we found that (R)-2-HG stimulated the growth of non-transformed cells, (R)-2-HG also displayed antitumor activity by suppressing the growth of tumors harboring wild type IDH2. The mitogenic effect of (R)-2-HG in immortalized cells could be switched to antiproliferative by transformation with oncogenic RAS. Thus, our findings show that despite their shared (R)-2-HG production, IDH2 mutations are not alike and differ in shaping tumor cell behavior and response to chemotherapeutic agents. Our study also reveals that under certain conditions, (R)-2-HG has antitumor properties.
000862731 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000862731 588__ $$aDataset connected to CrossRef
000862731 7001_ $$0P:(DE-HGF)0$$aRazmpour, Roshanak$$b1
000862731 7001_ $$0P:(DE-HGF)0$$aLutton, Evan$$b2
000862731 7001_ $$0P:(DE-Juel1)169976$$aAlfonso-Prieto, Mercedes$$b3$$ufzj
000862731 7001_ $$0P:(DE-HGF)0$$aRamirez, Servio H.$$b4
000862731 7001_ $$0P:(DE-HGF)0$$aGamero, Ana M.$$b5$$eCorresponding author
000862731 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.26848$$gVol. 10, no. 28$$n28$$p2675-2692$$tOncoTarget$$v10$$x1949-2553$$y2019
000862731 8564_ $$uhttps://juser.fz-juelich.de/record/862731/files/26848-1027930-1-PB.pdf$$yOpenAccess
000862731 8564_ $$uhttps://juser.fz-juelich.de/record/862731/files/26848-1027930-1-PB.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000862731 909CO $$ooai:juser.fz-juelich.de:862731$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000862731 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169976$$aForschungszentrum Jülich$$b3$$kFZJ
000862731 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000862731 9141_ $$y2019
000862731 915__ $$0LIC:(DE-HGF)CCBY3$$2HGFVOC$$aCreative Commons Attribution CC BY 3.0
000862731 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000862731 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000862731 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000862731 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000862731 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000862731 920__ $$lyes
000862731 9201_ $$0I:(DE-Juel1)IAS-5-20120330$$kIAS-5$$lComputational Biomedicine$$x0
000862731 9201_ $$0I:(DE-Juel1)INM-9-20140121$$kINM-9$$lComputational Biomedicine$$x1
000862731 980__ $$ajournal
000862731 980__ $$aVDB
000862731 980__ $$aUNRESTRICTED
000862731 980__ $$aI:(DE-Juel1)IAS-5-20120330
000862731 980__ $$aI:(DE-Juel1)INM-9-20140121
000862731 9801_ $$aFullTexts